## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Seveso et al.

Confirmation No.: 5272 Group Art Unit: 1635

Application No.: 09/743,173 Filed: January 14, 2002

Examiner: Jon E. Angell

For: ENHANCED DELIVERY OF NUCLEIC ACID-BASED DRUGS

April 7, 2010

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUBMITTAL OF REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY BY ASSIGNEE

Sir:

Enclosed herewith is copy of Form PTO/SB/81 (Revocation of Power of Attorney and New Power of Attorney, 1 page) and Form PTO/SB/96 (Statement Under 37 CFR 3.73(b), 2 pages) in reference to the above-identified patent.

Applicants do not believe that a fee is associated with this submission. However, should such a fee be required, the Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Robert A. Schwartzman, Ph.D. Registration No. 50,211

## USPTO Customer No. 20792

Myers Bigel Sibley & Sajovec

P.O. Box 37428

Raleigh, North Carolina 27627 Telephone: (919) 854-1400

Facsimile: (919) 854-1401

# CERTIFICATION OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on April 7, 2010.

Cianatura

Marthenn Salazar

PTO/SB/81 (01-09)

ENHANCED DELIVERY OF NUCLEIC ACID-BASED ...

Approved for use through 1130/2011. OMB 8651-0036

U.S. Petent and Tradesmark Office; U.S. DEPARTMENT OF COMMERCE
Under fine Paperwork Reduction Act of 1985, no persons are required to respond to a collection of Information unlessed ald playle a weld OMB control number.

09/743.173

January 14, 2002 Michele Seveso

	AND ALLOWER	Art Unit		1635			
			Examinar Nama		Jon E. Angell		
CHANGE OF COR	Attorney Docket						
						-	
I hereby revoke all pr	revious powers of attorney given	In the above-ide	entified a	pplication	on.		
A Power of Attorn	ey is submitted herewith.						
I hereby appoint P Number as my/our identified above, a and Trademark Of	application	20792					
[ ] I hareby appoint P	ractitioner(s) named below as my/our atte lness in the United States Patent and Tra	orney(s) or agent(s) demark Office conn	to prosecu acted there	ta the ap	plication identified above	and .	
Pri		Ragistration Number					
171						-	
Please recognize or o	change the correspondence addr	ess for the abov	re-Identifi	led app	elication to:		
The address assoc	clated with the above-menitoned Custome	ar Number.			_		
The address assoc	20792	20792					
Firm or Individual Name							
Address							
Cily	244-244-244-244-244-244-244-244-244-244	State	Ι		Zlp		
Talephone		Email	т —				
I am the:		Litten					
Applicant/Inventor.							
Assignee of record	of the entire trierest, Sea 37 CFR 3.71. 7 CFR 3.73(b) (Form PTO/SB/96) submitt	ed herewith or filed	on				
***************************************	SIGNATURE of Appl						
Signature Wiferer of			Date		6 April 10		
	THOMAS VV. LOSHEIL, I II.D.			phone	+1-918-797-1	847	
Title and Company V.P., C.S.O., Merrion Pharmaceuticals, LLC							
NOTE: Signatures of all like in alguature is required, see below	rountors or assignees of record of the entire int	erest or their represen	talive(a) are	required.	Submit multiple forms if mor	e than one	
Totel of1	forms are submitted.	-					

Application Number

First Named Inventor

Filing Date

Title

POWER OF ATTORNEY

OR

REVOCATION OF POWER OF ATTORNEY

MITH A NEW DOMED OF ATTORNEY

LIBERTON DESIGNATION OF THE ALL AS 2 M 1 43. THE Information is required to cotion or resign a borself by the public which is to life (and by the LIBERTON DESIGNATION DESIGNA

PTO(8886 (87.09)
Approved for use Brough 977.09(215.0 MB 9564, was 1
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control pumber.

STATEMENT UNDER	37 CFR 3.73(b)			
Applicant/Patent Owner: Seveso et al.				
Application No./Palent No.: 09/743,173	Filed/Issue Date: January 14, 2002			
Titled:				
Merrion Research III Limited , a corporat	lon			
(Nome of Assignee) (Type of A	esignee, e.g., corporation, partnership, university, government agency, etc.			
states that it is:				
the assignee of the entire right, title, and interest in; .				
an assignce of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is	%); or			
	nplete assignment from one of the joint inventors was made)			
the patent application/patent identified above, by virtue of either:				
An assignment from the Inventor(s) of the patent application the United States Patent and Trademark Office at Reel copy therefore is attached.  OR	/patent identified above. The assignment was recorded in, or for which a			
B. X A chain of title from the inventor(s), of the patent application/	patent identified shows to the suggest and a first			
— (-) - the parent approaches	To: Adaptiv Biopharma Limited			
The document was recorded in the United States if				
Reel 015982 Frame 0314	Patent and Trademark Office at			
From: Adaptiv Biopharma Limited	To: Merrion Blopharma Limited			
The document was recorded in the United States I	Patent and Trademark Office at			
Reel 015979 , Frame 0810	or for which a copy thereof is attached.			
From: Merrion Blopharma Llmited				
The document was recorded in the United States F	Patent and Trademark Office at			
Reel 022174 Frame 0591	or for which a copy thereof is attached.			
Additional documents in the chain of title, are listed on a sup-				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence or concurrently is being, submitted for recordation pursuant to 37	of the chain of title from the original owner to the assignee was, CFR 3.11.			
[NOTE: A separate copy (I.e., a true copy of the original assignm accordance with 37 CFR Part 3, to record the assignment in the re	ant document(a)) must be submitted to Assistance to the training			
The undersigned (whose title is supplied below) is authorized to act on b	ehalf of the assignee.			
appenend	,			
Signature	6 April 10			
Thomas W. Leonard	V.P., C.S.O., Merrion Pharms			
Printed or Typed Name	Title			
his collection of information is required by 37 CFR 3,73(b). The totormetion is required to ob- rocess) an application. Confidenticity is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1	late as setale a base of the first out the state of the first of the state of the s			

processly an opporation. Conditionality is governed by 30 L.S.C. 192 and 37 CFR 1.11 and 1.4. This collection is estimated to take 12 intrinses to complete, including your requires to complete including your requires to complete including complete processing on the LMSP107. There will wave giaserating upon the including collection of the processing of

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant: Seveso et al. Application No,: 09/743,173 Filed: January 14, 2002

Supplemental Sheet - Chain of Title

A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

4. From: Merrion Research I Limited

To: Merrion Research Il Limited

The document was recorded in the United States Patent and Trademark Office at Reel 021141, Frame 0871

5, From; Merrion Research II Limited

To: Merrion Research III Limited

The document was recorded in the United States Patent and Trademark Office at Reel 021189, Frame 0291